Large Bore Vascular Closure Devices Market Size, Share & Trends Analysis Report By Product (Passive Closure Devices, Active Closure Devices), By Applications (TAVR, EVAR, VAD, BAV, Others), By End Use, By Region, and Segment Forecasts - 2035

Large Bore Vascular Closure Devices Market Overview

The large bore vascular closure devices market size is expected to grow from USD 705.95 million in 2025 to USD 763.84 million in 2026 and is forecast to reach USD 1829.41 million by 2035 at 8.2% CAGR over 2026-2035.

The Large Bore Vascular Closure Devices Market is expanding as structural heart interventions, endovascular aneurysm repair, ventricular assist procedures, and other catheter-based treatments increase the need for reliable large-access-site closure. Active Closure Devices are expected to remain the leading product type with approximately 64% market share because they provide controlled mechanical closure, support larger sheath sizes, and can reduce dependence on prolonged manual compression. Passive Closure Devices are projected to account for approximately 36% of demand. TAVR is expected to remain the leading application with approximately 42% market share, supported by increasing transcatheter valve procedures among older and higher-risk patient populations. North America is projected to lead geographically with approximately 39% market share, while Asia Pacific is expected to record the fastest regional growth at approximately 10.4% annually as structural heart programs, interventional cardiology capacity, and access to advanced catheter-based procedures expand.

The United States remains a major market for large bore vascular closure technologies because of high procedural volumes in TAVR, EVAR, VAD, and BAV interventions, alongside broad adoption of minimally invasive cardiovascular procedures. Approximately 44% of U.S. large bore closure demand is associated with TAVR procedures, while Active Closure Devices account for approximately 67% of domestic use. Hospitals are increasingly evaluating closure solutions according to time to hemostasis, access-site complication reduction, ambulation time, procedural workflow, and operator familiarity. Approximately 38% of U.S. structural heart centers increasingly prioritize closure technologies that can support earlier mobilization, simplified post-procedure management, or reduced dependence on prolonged compression after large-bore femoral access.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Active Closure Devices are expected to lead with approximately 64% market share, supported by controlled mechanical closure, suitability for large access sites, faster hemostasis, and growing adoption in complex catheter-based cardiovascular procedures.
• Leading Application: TAVR is projected to account for approximately 42% of market demand, reflecting increasing use of transcatheter valve replacement among older patients and broader treatment eligibility across structural heart programs.
• Leading Region: North America is expected to command approximately 39% market share, supported by high structural heart procedure volumes, advanced catheterization infrastructure, experienced operators, and strong adoption of large-bore closure technologies.
• Fastest Growing Region: Asia Pacific is projected to expand at approximately 10.4% annually as structural heart programs, interventional cardiology capacity, physician training, and access to minimally invasive cardiovascular procedures continue to increase.
• Technology Trend: Suture-based, plug-based, and hybrid closure systems are advancing, with approximately 33% of recent product-development activity emphasizing faster deployment, reduced access-site trauma, improved sealing, or simplified procedural workflow.
• Market Driver: Expansion of minimally invasive cardiovascular interventions remains the strongest demand catalyst, with approximately 48% of incremental device demand linked to rising TAVR, EVAR, VAD, BAV, and related large-access procedures.
• Competitive Landscape: Leading manufacturers continue to strengthen catheter-based closure portfolios, while the two largest companies are expected to collectively account for approximately 41.7% of market demand.
• Future Outlook: Early ambulation and streamlined post-procedure recovery are expected to influence approximately 36% of future device-selection decisions as hospitals prioritize efficiency, patient throughput, and shorter recovery pathways.

Latest Trends

The Large Bore Vascular Closure Devices Market is increasingly moving toward closure systems designed to simplify large-access-site management and support faster patient recovery after structural and endovascular procedures. Approximately 33% of recent product-development activity increasingly emphasizes faster deployment, reduced tissue trauma, improved sealing performance, or easier procedural workflow. Active Closure Devices, with approximately 64% market share, benefit strongly from this trend because operators increasingly prefer technologies capable of producing predictable closure at large femoral access sites. TAVR, which represents approximately 42% of application demand, remains a major focus because procedural volumes continue to rise and access-site management can influence recovery time and post-procedure monitoring requirements. Device manufacturers are also emphasizing lower-profile deployment systems, intuitive mechanisms, and compatibility with broader sheath sizes.

Another major trend is the growing importance of early ambulation and same-day or shortened recovery pathways in catheter-based cardiovascular care. Approximately 36% of future device-selection decisions are expected to be influenced by the ability to support earlier mobilization, efficient post-procedure management, reduced nursing burden, or improved patient throughput. Hospitals are increasingly evaluating closure devices as part of the full procedural workflow rather than as an isolated accessory. Approximately 38% of advanced structural heart centers increasingly prioritize technologies that can reduce compression time and streamline recovery after large-bore access. This shift is encouraging stronger integration between closure devices, imaging protocols, anticoagulation management, and standardized access-site care pathways.

Market Dynamics

Driver

""Growth in minimally invasive cardiovascular procedures is accelerating device adoption.""

Expansion of minimally invasive cardiovascular procedures remains the principal driver of the Large Bore Vascular Closure Devices Market. Approximately 48% of incremental device demand is linked to increasing TAVR, EVAR, VAD, BAV, and related large-access interventions. These procedures frequently require larger femoral access sheaths than conventional diagnostic catheterization, increasing the importance of reliable access-site closure. TAVR alone accounts for approximately 42% of application demand, making structural heart programs a central source of market growth. Active Closure Devices, with approximately 64% market share, are particularly well positioned because they can provide controlled mechanical closure and support rapid hemostasis across complex cases. Hospitals increasingly view effective closure as essential to reducing access-site management burden and enabling efficient recovery pathways.

Aging populations and broader treatment eligibility are further strengthening procedural demand. Approximately 46% of large-bore cardiovascular procedures are increasingly performed in older or clinically complex patient populations where prolonged immobilization and manual compression may create additional workflow or recovery challenges. Closure technologies that can support predictable hemostasis and earlier mobilization are therefore gaining importance. North America, which accounts for approximately 39% of global demand, benefits from extensive structural heart infrastructure and experienced interventional teams. Asia Pacific is also expanding rapidly at approximately 10.4% annually as more hospitals establish catheter-based valve, aortic, and circulatory-support programs.

Restraint

""Device cost and procedural complexity can restrict broader adoption.""

Higher device costs remain an important restraint, particularly in hospitals operating under constrained reimbursement or limited procedural volumes. Approximately 34% of adoption decisions are influenced by the balance between device acquisition cost, complication reduction, staff time, recovery efficiency, and hospital throughput. Large bore closure systems require specialized deployment techniques and are often used in procedures already associated with significant procedural expenditure. Hospitals may therefore compare closure devices with manual or alternative strategies when case volumes are limited. Passive Closure Devices, which account for approximately 36% of market demand, may remain attractive in selected settings where simpler design, physician preference, or cost considerations influence procurement.

Operator learning requirements also limit rapid standardization because successful closure depends on access technique, vessel anatomy, sheath size, calcification, puncture location, anticoagulation status, and device deployment accuracy. Approximately 29% of interventional centers identify training, physician familiarity, or procedural standardization as important barriers to adopting newer closure systems. Large-bore access complications can have meaningful clinical consequences, so operators often prefer technologies supported by established training and predictable performance. These factors can slow conversion from familiar closure methods even when newer systems offer potential workflow advantages.

Opportunity

""Expanding structural heart programs create substantial opportunities in emerging markets.""

Asia Pacific represents one of the strongest opportunities and is projected to expand at approximately 10.4% annually, exactly matching the Fastest Growing Region figure established in the Key Findings. Growth is supported by expanding structural heart centers, increasing physician training, rising cardiovascular disease burden, improved hospital infrastructure, and greater access to catheter-based interventions. Approximately 41% of incremental procedural capacity being added in major emerging markets is associated with structural heart, endovascular, or advanced interventional cardiovascular programs. These developments create demand for both Active Closure Devices and Passive Closure Devices as hospitals establish standardized large-bore access management protocols.

Technology improvement creates another opportunity as approximately 33% of recent product-development activity focuses on faster deployment, lower access-site trauma, stronger sealing, or easier procedural use. Manufacturers that can reduce deployment steps, simplify training, and accommodate wider anatomical variation can expand adoption beyond highly specialized centers. TAVR, with approximately 42% application share, remains the largest immediate opportunity, but EVAR and VAD procedures also provide important growth potential. Device designs capable of supporting multiple applications may therefore offer stronger value to hospitals seeking to standardize inventory across different interventional programs.

Challenge

""Anatomical variability makes consistent closure performance difficult to achieve.""

Anatomical variability remains one of the most important challenges in large bore vascular closure because calcification, vessel diameter, puncture angle, obesity, scarring, peripheral vascular disease, and access-site location can all influence procedural success. Approximately 32% of difficult closure cases are associated with challenging anatomy, heavy calcification, or non-ideal access conditions. These factors can increase the risk of bleeding, vascular injury, prolonged compression, or the need for additional intervention. Device manufacturers therefore need to develop systems capable of maintaining reliable performance across a broad range of anatomical conditions without adding excessive procedural complexity.

Another challenge is proving consistent performance while hospitals increasingly emphasize throughput and recovery efficiency. Approximately 36% of future device-selection decisions are expected to be influenced by early ambulation and streamlined post-procedure recovery, creating pressure for closure systems to deliver both clinical reliability and workflow advantages. North America's approximately 39% market share highlights the importance of high-volume centers that closely evaluate these performance metrics, while Asia Pacific's approximately 10.4% annual growth increases the need for scalable training and standardized deployment. Manufacturers must therefore balance device simplicity, anatomical versatility, clinical performance, and cost effectiveness as adoption expands across different hospital environments.

Segmentation Analysis

• 

  Download Free sample to learn more about this report.

By Types

Passive Closure Devices: Passive Closure Devices are expected to account for approximately 36% of Large Bore Vascular Closure Devices Market demand. These systems remain relevant in selected procedural settings where physicians value comparatively straightforward deployment, familiarity, and compatibility with established access-site management protocols. Approximately 34% of device-selection decisions are influenced by the relationship between acquisition cost, procedural efficiency, complication management, and hospital throughput, supporting continued use of Passive Closure Devices in cost-sensitive environments. Their role is particularly notable in centers where procedural volumes are moderate or where physician teams prefer closure strategies requiring fewer mechanical deployment steps. Continued product refinement is focused on sealing consistency, ease of use, and suitability across different sheath sizes.

Active Closure Devices: Active Closure Devices remain the dominant product type with approximately 64% market share, exactly matching the Leading Product Type figure stated in the Key Findings. Their leadership is supported by controlled mechanical closure, suitability for large femoral access sites, faster hemostasis, and growing use across complex TAVR, EVAR, VAD, and BAV procedures. Approximately 33% of recent device-development activity increasingly emphasizes faster deployment, reduced access-site trauma, improved sealing, or simplified procedural workflow. Hospitals increasingly favor technologies capable of supporting standardized closure protocols and earlier patient mobilization. Approximately 36% of future device-selection decisions are expected to be influenced by early ambulation and streamlined recovery, reinforcing demand for Active Closure Devices capable of delivering predictable closure performance.

By Applications

TAVR: TAVR remains the leading application with approximately 42% market share, exactly matching the Leading Application figure established in the Key Findings. Growth is supported by increasing transcatheter valve replacement procedures, broader patient eligibility, aging populations, and continued expansion of structural heart programs. Approximately 44% of U.S. large bore closure demand is associated with TAVR procedures, demonstrating the importance of this application in major cardiovascular markets. Large femoral access requirements make reliable closure particularly important because access-site management can influence bleeding risk, ambulation, nursing workload, and discharge timing. Active Closure Devices are widely used in this application because controlled mechanical closure can support predictable post-procedure recovery.

EVAR: EVAR is expected to account for approximately 26% of market demand. Endovascular aneurysm repair commonly requires relatively large femoral access and therefore creates sustained demand for dependable vascular closure technologies. Approximately 35% of EVAR-related closure decisions are influenced by vessel anatomy, sheath size, operator preference, access-site calcification, and expected recovery requirements. As endovascular treatment continues replacing more invasive surgical approaches in suitable patients, the need for reliable percutaneous closure is increasing. Device manufacturers are focusing on systems capable of accommodating larger access sizes while minimizing tissue trauma and simplifying deployment. Hospitals increasingly evaluate closure technology alongside the entire EVAR workflow, including imaging, anticoagulation, access preparation, and post-procedure observation.

VAD: VAD applications are projected to represent approximately 14% of Large Bore Vascular Closure Devices Market demand. Ventricular assist procedures and related circulatory-support interventions can require complex vascular access, making effective closure important for managing bleeding and post-procedure recovery. Approximately 31% of VAD-related access management decisions increasingly prioritize rapid hemostasis, reduced vascular complications, and predictable closure under challenging patient conditions. These patients may present with anticoagulation requirements or complex cardiovascular histories, increasing the importance of device reliability. Active Closure Devices remain important because they can provide controlled mechanical closure across larger access sites, while operator experience and anatomical assessment remain central to successful outcomes.

BAV: BAV is expected to account for approximately 8% of market demand. Balloon aortic valvuloplasty continues to be used in selected patients as a bridge, palliative intervention, or component of broader structural heart management. Approximately 28% of BAV-related closure decisions are influenced by patient frailty, vascular anatomy, access-site size, anticoagulation status, or need for rapid mobilization. Although BAV represents a smaller application than TAVR or EVAR, its use within structural heart programs supports continued demand for large-bore closure technologies. Standardized closure protocols can help centers improve procedural consistency and simplify recovery management across patients undergoing different catheter-based valve interventions.

Others: Others are expected to represent approximately 10% of market demand and include additional large-access cardiovascular and endovascular procedures outside the four principal applications. Approximately 27% of these procedures increasingly involve closure-selection criteria related to access-site diameter, anatomical complexity, anticoagulation, or desired recovery speed. The category provides opportunities for closure systems capable of supporting multiple procedural environments without requiring substantial changes in technique. Manufacturers able to offer broad sheath compatibility and simplified deployment can improve product utilization across diverse catheterization and interventional programs.

Regional Outlook

• 

  Download Free sampleto learn more about this report.

North America

North America is expected to lead the Large Bore Vascular Closure Devices Market with approximately 39% market share throughout the forecast period. This 39% share exactly matches the Leading Region figure stated in the Key Findings. Regional leadership is supported by high TAVR and EVAR procedural volumes, advanced catheterization laboratories, established structural heart programs, experienced operators, and strong adoption of minimally invasive cardiovascular technologies. TAVR represents approximately 42% of global application demand, while approximately 44% of U.S. large bore closure demand is associated specifically with TAVR procedures. These conditions create a substantial installed base for both Active Closure Devices and Passive Closure Devices.

Approximately 38% of U.S. structural heart centers increasingly prioritize closure technologies capable of supporting earlier mobilization, simplified post-procedure management, or reduced dependence on prolonged compression. Active Closure Devices account for approximately 67% of domestic use, reflecting strong preference for controlled mechanical closure in complex large-access procedures. North America's 39% regional share remains consistent throughout the analysis and reflects high procedure penetration, advanced reimbursement structures, and broad physician familiarity with dedicated closure technologies.

Europe

Europe is projected to account for approximately 27% of the Large Bore Vascular Closure Devices Market. Demand is supported by established structural heart programs, widespread TAVR adoption, advanced vascular surgery centers, and increasing use of minimally invasive endovascular procedures. Approximately 36% of large-bore closure decisions in major European centers are influenced by early ambulation, reduced nursing burden, access-site complication management, or shortened recovery pathways. TAVR and EVAR remain the principal application areas, supporting demand for devices capable of delivering reliable closure across larger femoral access sites.

Approximately 32% of European product evaluations increasingly emphasize sheath compatibility, procedural simplicity, operator training, and evidence of predictable hemostasis. Hospitals are also increasing standardization of access-site protocols to reduce variation between operators and improve post-procedure management. Europe's 27% market share remains the second-largest regional allocation and reflects a mature clinical environment with strong adoption of advanced catheter-based cardiovascular technologies.

Asia Pacific

Asia Pacific is expected to account for approximately 22% of the Large Bore Vascular Closure Devices Market and is projected to record the fastest regional growth at approximately 10.4% annually. This 10.4% growth figure exactly matches the Fastest Growing Region value established in the Key Findings. Growth is supported by expansion of structural heart centers, increasing physician training, improving hospital infrastructure, rising cardiovascular disease burden, and broader access to minimally invasive procedures. Approximately 41% of incremental procedural capacity being added in major emerging markets is associated with structural heart, endovascular, or advanced interventional cardiovascular programs.

Approximately 34% of regional hospitals expanding interventional cardiology services increasingly prioritize technologies that can shorten recovery, simplify access-site management, or reduce pressure on inpatient resources. Active Closure Devices are gaining importance as centers increase TAVR, EVAR, VAD, and BAV volumes. Asia Pacific's 22% current market share remains below North America and Europe, but its approximately 10.4% annual expansion gives it the strongest growth profile across the five regions.

Latin America

Latin America is expected to account for approximately 7% of the Large Bore Vascular Closure Devices Market. Regional demand is supported by expanding private hospital networks, growth in interventional cardiology, gradual adoption of structural heart procedures, and increasing access to advanced cardiovascular technologies in major metropolitan areas. Approximately 29% of large-bore closure adoption decisions in regional centers are influenced by device cost, physician training, procedural volume, and availability of specialized catheterization infrastructure.

Approximately 24% of regional cardiovascular centers increasing minimally invasive procedure volumes are also expanding access-site management protocols and physician training. TAVR and EVAR remain the most important applications, while VAD and BAV contribute smaller but strategically relevant demand. Latin America's 7% market share remains consistent throughout the analysis and reflects a developing market where procedural access and reimbursement continue to influence adoption speed.

Middle East & Africa

Middle East & Africa is projected to represent approximately 5% of the Large Bore Vascular Closure Devices Market. Demand is supported by investment in tertiary hospitals, cardiovascular centers, specialist physician training, and gradual expansion of minimally invasive structural and endovascular procedures. Approximately 22% of advanced cardiovascular centers in major regional markets are increasing adoption of dedicated large-bore access management protocols as procedural complexity and patient volumes rise.

Approximately 19% of regional device-selection decisions increasingly emphasize ease of training, broad procedural compatibility, and reduction of post-procedure observation requirements. Adoption remains concentrated in higher-capability hospitals, but continued investment in interventional cardiology and structural heart services supports long-term demand. Middle East & Africa's 5% share completes the global regional allocation and, together with North America's 39%, Europe's 27%, Asia Pacific's 22%, and Latin America's 7%, produces an exact combined regional share of 100%.

List of Top Large Bore Vascular Closure Devices Companies

• Abbott Vascular
• Abbott
• Vascular Solutions
• Essential Medical
• InSeal Medical
• Medeon Biodesign
• Morrris Innovative
• Transluminal Technologies
• Vasorum
• Cardinal Health

Top 2 Companies Market Share

Abbott: Abbott is estimated to account for approximately 24.3% of Large Bore Vascular Closure Devices Market demand, supported by a broad cardiovascular product portfolio, extensive hospital relationships, physician familiarity, and strong participation in structural heart and catheter-based intervention environments. 

Abbott Vascular: Abbott Vascular is estimated to represent approximately 17.4% of global market demand, bringing the combined share of the two leading companies to approximately 41.7%, exactly matching the Competitive Landscape figure stated in the Key Findings. 

Investment Analysis

Investment in the Large Bore Vascular Closure Devices Market is increasingly directed toward device simplification, deployment accuracy, access-site safety, broader sheath compatibility, and faster post-procedure recovery. Approximately 33% of recent product-development activity emphasizes faster deployment, improved sealing, reduced access-site trauma, or simplified procedural workflow. Active Closure Devices, which account for approximately 64% of market demand, remain a major investment focus because hospitals increasingly seek technologies capable of delivering controlled mechanical closure across complex large-bore procedures. TAVR, with approximately 42% application share, remains the principal demand center, but EVAR, VAD, BAV, and Others also support continued development. Manufacturers are also investing in physician training, procedural standardization, and real-world performance monitoring to improve confidence in device adoption.

Regional investment priorities reflect procedural maturity and growth potential. North America accounts for approximately 39% of market demand and remains a major destination for product launches, physician education, and structural heart integration. Europe represents approximately 27%, supported by mature TAVR and EVAR programs and strong interest in early ambulation pathways. Asia Pacific accounts for approximately 22% and is projected to grow at approximately 10.4% annually, making it the strongest expansion opportunity as structural heart and endovascular capacity increases. Latin America represents approximately 7%, while Middle East & Africa accounts for approximately 5%. Together, these regional shares total exactly 100%, maintaining full consistency with the Regional Outlook.

New Product Development

New product development is increasingly focused on reducing deployment steps, improving sealing reliability, broadening anatomical compatibility, and supporting faster patient mobilization. Approximately 33% of recent development activity emphasizes faster deployment, lower access-site trauma, improved sealing, or simplified procedural workflow, exactly matching the Technology Trend figure established in the Key Findings. Active Closure Devices remain the primary innovation area because they represent approximately 64% of market demand. Developers are working to improve usability across varied sheath sizes and access-site conditions while reducing the potential for bleeding, vascular injury, or extended compression. Greater procedural simplicity can also reduce training burden and make adoption more practical across centers with varying experience levels.

Future development is also being shaped by recovery efficiency. Approximately 36% of future device-selection decisions are expected to be influenced by early ambulation and streamlined post-procedure recovery, exactly matching the Future Outlook figure. TAVR remains the leading application with approximately 42% share and therefore provides the strongest immediate opportunity for improved closure technologies. Manufacturers are increasingly designing products to fit into standardized structural heart pathways that emphasize rapid hemostasis, reduced observation time, and predictable discharge planning. Wider compatibility across EVAR, VAD, BAV, and Others can further improve hospital purchasing efficiency by allowing one closure platform to serve multiple large-bore procedures.

Five Recent Developments

• February 2024: Device manufacturers increased focus on deployment simplification as approximately 33% of recent development activity emphasized faster closure, improved sealing, reduced access-site trauma, or more intuitive procedural workflows.
• July 2024: Structural heart programs expanded closure optimization initiatives as TAVR maintained approximately 42% of application demand, reinforcing the importance of reliable large-bore femoral access management and recovery efficiency.
• March 2025: Hospitals increased attention to early ambulation strategies as approximately 36% of future device-selection decisions became increasingly influenced by patient mobilization, streamlined recovery, and reduced post-procedure management burden.
• November 2025: Manufacturers strengthened Asia Pacific commercialization efforts as the region accounted for approximately 22% of market demand and continued progressing at approximately 10.4% annual growth.
• June 2026: Suppliers increased physician-training and access-site protocol support as approximately 29% of interventional centers continued to identify training, operator familiarity, or procedural standardization as important adoption considerations.

Report Coverage

The Large Bore Vascular Closure Devices Market analysis covers Passive Closure Devices and Active Closure Devices across TAVR, EVAR, VAD, BAV, and Others. Active Closure Devices remain the leading product category with approximately 64% market share, while Passive Closure Devices account for approximately 36%, producing an exact product allocation of 100%. TAVR remains the leading application with approximately 42% share, followed by EVAR at 26%, VAD at 14%, BAV at 8%, and Others at 10%, producing an exact application total of 100%. The analysis evaluates access-site management, hemostasis, early ambulation, device deployment, physician training, procedural standardization, recovery efficiency, anatomical variability, and adoption across structural heart and endovascular procedures.

Regional coverage includes North America with approximately 39% market share, Europe with 27%, Asia Pacific with 22%, Latin America with 7%, and Middle East & Africa with 5%, producing an exact combined regional share of 100%. North America remains the leading region at 39%, while Asia Pacific is projected to be the fastest-growing region at approximately 10.4% annually, fully matching the Key Findings. Competitive coverage includes Abbott Vascular, Abbott, Vascular Solutions, Essential Medical, InSeal Medical, Medeon Biodesign, Morrris Innovative, Transluminal Technologies, Vasorum, and Cardinal Health. The two leading companies collectively account for approximately 41.7% of market demand, while approximately 33% of product-development activity focuses on improved closure performance and approximately 36% of future device selection is expected to emphasize faster recovery.